Spoken Alpha
XFOR
X4 Pharmaceuticals, Inc
Overview
X4 Pharmaceuticals develops and commercializes oral therapeutics for rare blood disorders. The company's lead product, mavorixafor (XOLREMDI), is FDA-approved for WHIM syndrome and in Phase 3 trials for chronic neutropenia. X4 also licenses its CXCR4 antagonist technology to international partners for commercialization in Europe and other regions.
X4 Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $314.3M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
16 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-10-04.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2025Earnings2025-05-0111 Q&A exchanges
- Q4 FY2024Earnings2025-03-2519 Q&A exchanges
- Q3 FY2024Earnings2024-11-1314 Q&A exchanges
- Q1 FY2024Earnings2024-05-0716 Q&A exchanges
- Q4 FY2023Earnings2024-03-2112 Q&A exchanges
- Q3 FY2023Earnings2023-11-0922 Q&A exchanges
- Q2 FY2023Earnings2023-08-1014 Q&A exchanges
- Q1 FY2023Earnings2023-05-0615 Q&A exchanges
- Q4 FY2022Earnings2023-03-2117 Q&A exchanges
- Q3 FY2022Earnings2022-11-0514 Q&A exchanges
- Q2 FY2022Earnings2022-08-0715 Q&A exchanges
- Q1 FY2022Earnings2022-05-1213 Q&A exchanges
- Q4 FY2021Earnings2022-03-1718 Q&A exchanges
- Q3 FY2021Earnings2021-11-0512 Q&A exchanges
- Q2 FY2021Earnings2021-08-0627 Q&A exchanges
- Q1 FY2021Earnings2021-05-0914 Q&A exchanges
History
Earnings history
- Q3 FY20262026-11-03EPS— vs $-0.19—Rev— vs ——EODHD
- Q2 FY20262026-08-05EPS$-0.13 vs $-0.19+31.6%Rev$8.8M vs ——EODHD
- Q1 FY20262026-05-05EPS$-0.16 vs $-0.20+20.0%Rev$2.7M vs ——EODHD
- Q4 FY20252026-03-16EPS$-0.22 vs $-0.35+36.7%Rev$2.6M vs ——EODHD
- Q3 FY20252025-11-04EPS$-0.69 vs $-0.79+12.7%Rev$1.8M vs ——EODHD
- Q2 FY20252025-08-07EPS$-3.47 vs $-4.34+20.1%Rev$2.0M vs ——EODHD
- Q1 FY20252025-04-30EPS$0.04 vs $-3.75+100.0%Rev$28.8M vs ——EODHD
- Q4 FY20242025-03-18EPS$-0.20 vs $-0.16-27.0%Rev$1.4M vs ——EODHD
- Q3 FY20242024-11-12EPS$-5.40 vs $-5.16-4.7%Rev$560.0K vs ——EODHD
- Q2 FY20242024-08-07EPS$-2.12 vs $0.75-100.0%Rev$563.0K vs ——EODHD
- Q1 FY20242024-05-06EPS$-0.26 vs $-0.16-62.5%Rev$0 vs ——EODHD
- Q4 FY20232024-03-20EPS$-3.00 vs $-4.55+34.1%Rev$3.1M vs ——EODHD
- Q3 FY20232023-11-08EPS$-0.30 vs $-4.29+93.0%Rev$0 vs ——EODHD
- Q2 FY20232023-08-09EPS$-9.90 vs $-4.93-100.0%Rev$0 vs ——EODHD
- Q1 FY20232023-05-03EPS$-0.16 vs $-0.22+27.3%Rev$0 vs ——EODHD
- Q4 FY20222023-03-20EPS$-8.70 vs $-7.24-20.2%Rev$0 vs ——EODHD
- Q3 FY20222022-11-02EPS$-7.80 vs $-9.53+18.1%Rev$0 vs ——EODHD
- Q2 FY20222022-08-03EPS$-18.00 vs $-19.25+6.5%Rev$0 vs ——EODHD
- Q1 FY20222022-05-11EPS$-21.60 vs $-18.53-16.6%Rev$0 vs ——EODHD
- Q4 FY20212022-03-16EPS$-0.90 vs $-0.68-32.4%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-0.19 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $-0.13 | $-0.19 | +31.6% | $8.8M | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $-0.16 | $-0.20 | +20.0% | $2.7M | — | — | EODHD |
| Q4 FY2025 | 2026-03-16 | $-0.22 | $-0.35 | +36.7% | $2.6M | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.69 | $-0.79 | +12.7% | $1.8M | — | — | EODHD |
| Q2 FY2025 | 2025-08-07 | $-3.47 | $-4.34 | +20.1% | $2.0M | — | — | EODHD |
| Q1 FY2025 | 2025-04-30 | $0.04 | $-3.75 | +100.0% | $28.8M | — | — | EODHD |
| Q4 FY2024 | 2025-03-18 | $-0.20 | $-0.16 | -27.0% | $1.4M | — | — | EODHD |
| Q3 FY2024 | 2024-11-12 | $-5.40 | $-5.16 | -4.7% | $560.0K | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-2.12 | $0.75 | -100.0% | $563.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $-0.26 | $-0.16 | -62.5% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-20 | $-3.00 | $-4.55 | +34.1% | $3.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.30 | $-4.29 | +93.0% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-9.90 | $-4.93 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.16 | $-0.22 | +27.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-20 | $-8.70 | $-7.24 | -20.2% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-7.80 | $-9.53 | +18.1% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-18.00 | $-19.25 | +6.5% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-21.60 | $-18.53 | -16.6% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-16 | $-0.90 | $-0.68 | -32.4% | $0 | — | — | EODHD |
Source: EODHD. XFOR reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for XFOR.
$ curl https://api.spokenalpha.com/v1/companies/XFORFAQ
Frequently asked about XFOR
Where can I find X4 Pharmaceuticals, Inc's (XFOR) earnings call transcripts?
Spoken Alpha indexes XFOR's earnings call transcripts at https://spokenalpha.com/companies/XFOR. Each call links to attributed speakers and parsed analyst Q&A. X4 Pharmaceuticals, Inc's own investor relations page is at https://investors.x4pharma.com/.
When was X4 Pharmaceuticals, Inc's most recent earnings call?
X4 Pharmaceuticals, Inc (XFOR) held its most recent earnings call on 2025-05-01, covering fiscal Q1 2025.
What sector is XFOR in?
X4 Pharmaceuticals, Inc (XFOR) operates in the Healthcare sector (Biotechnology industry).